메뉴 건너뛰기




Volumn 13, Issue 4, 2007, Pages 337-348

Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices

Author keywords

Adult medical oncology; Community practice; Febrile neutropenia; Growth factors; Outcomes research; Patient management; Supportive care

Indexed keywords

CHLORMETHINE; CLADRIBINE; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; FLUDARABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

EID: 34250717295     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.4.337     Document Type: Article
Times cited : (108)

References (40)
  • 1
    • 24944494962 scopus 로고    scopus 로고
    • A process for measuring the quality of cancer care: The Quality Oncology Practice Initiative
    • Neuss MN, Desch CE, McNiff KK, et al. A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol. 2005;23:6233-39.
    • (2005) J Clin Oncol , vol.23 , pp. 6233-6239
    • Neuss, M.N.1    Desch, C.E.2    McNiff, K.K.3
  • 2
    • 4143132329 scopus 로고    scopus 로고
    • Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality
    • Schneider EC, Epstein AM, Malin JL, et al. Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality. J Clin Oncol. 2004;22:2985-91.
    • (2004) J Clin Oncol , vol.22 , pp. 2985-2991
    • Schneider, E.C.1    Epstein, A.M.2    Malin, J.L.3
  • 3
    • 12444272754 scopus 로고    scopus 로고
    • Medicare demonstration projects acknowledge evidence-based medicine in cancer care
    • Twombly R. Medicare demonstration projects acknowledge evidence-based medicine in cancer care. J Natl Cancer Inst. 2005;97:6-7.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 6-7
    • Twombly, R.1
  • 4
    • 0037291748 scopus 로고    scopus 로고
    • Outcomes research at the National Cancer Institute: Measuring, understanding, and improving the outcomes of cancer care
    • Lipscomb J, Donaldson MS. Outcomes research at the National Cancer Institute: measuring, understanding, and improving the outcomes of cancer care. Clin Ther. 2003;25:699-712.
    • (2003) Clin Ther , vol.25 , pp. 699-712
    • Lipscomb, J.1    Donaldson, M.S.2
  • 5
    • 4444367159 scopus 로고    scopus 로고
    • Bridging the divide: Integrating cancer-directed therapy and palliative care
    • Malin JL. Bridging the divide: integrating cancer-directed therapy and palliative care. J Clin Oncol. 2004;22:3438-40.
    • (2004) J Clin Oncol , vol.22 , pp. 3438-3440
    • Malin, J.L.1
  • 7
    • 0042259168 scopus 로고    scopus 로고
    • Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy
    • Crawford J. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy. 2003;23:15S-19S.
    • (2003) Pharmacotherapy , vol.23
    • Crawford, J.1
  • 8
    • 27744493302 scopus 로고    scopus 로고
    • Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: A review of the evidence
    • Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw. 2005;3:557-71.
    • (2005) J Natl Compr Canc Netw , vol.3 , pp. 557-571
    • Lyman, G.H.1
  • 9
    • 0028909867 scopus 로고
    • Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up
    • Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901-06.
    • (1995) N Engl J Med , vol.332 , pp. 901-906
    • Bonadonna, G.1    Valagussa, P.2    Moliterni, A.3
  • 10
    • 11344273935 scopus 로고    scopus 로고
    • Dose and schedule as determinants of outcomes in chemotherapy for breast cancer
    • Budman DR. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer. Semin Oncol. 2004;31 (suppl 15):3-9.
    • (2004) Semin Oncol , vol.31 , Issue.SUPPL. 15 , pp. 3-9
    • Budman, DR.1
  • 11
    • 11344274427 scopus 로고    scopus 로고
    • The importance of chemotherapy dose intensity in lung cancer
    • Crawford J. The importance of chemotherapy dose intensity in lung cancer. Semin Oncol. 2004;31(suppl 15):25-31.
    • (2004) Semin Oncol , vol.31 , Issue.SUPPL. 15 , pp. 25-31
    • Crawford, J.1
  • 12
    • 0025363033 scopus 로고
    • Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis
    • Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963-77.
    • (1990) J Clin Oncol , vol.8 , pp. 963-977
    • Kwak, L.W.1    Halpern, J.2    Olshen, R.A.3
  • 13
    • 0027495838 scopus 로고
    • Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte)
    • Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol. 1993;4:651-56.
    • (1993) Ann Oncol , vol.4 , pp. 651-656
    • Lepage, E.1    Gisselbrecht, C.2    Haioun, C.3
  • 14
    • 17644379037 scopus 로고    scopus 로고
    • Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy
    • Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy Cancer. 2005;103: 1916-24.
    • (2005) Cancer , vol.103 , pp. 1916-1924
    • Caggiano, V.1    Weiss, R.V.2    Rickert, T.S.3
  • 15
    • 0025800331 scopus 로고
    • Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
    • Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-70.
    • (1991) N Engl J Med , vol.325 , pp. 164-170
    • Crawford, J.1    Ozer, H.2    Stoller, R.3
  • 16
    • 0037250159 scopus 로고    scopus 로고
    • A randomized double-blind multi-center phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
    • Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multi-center phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol. 2003;14:29-35.
    • (2003) Ann Oncol , vol.14 , pp. 29-35
    • Green, M.D.1    Koelbl, H.2    Baselga, J.3
  • 17
    • 0027390482 scopus 로고
    • Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
    • Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319-24.
    • (1993) Eur J Cancer , vol.29 A , pp. 319-324
    • Trillet-Lenoir, V.1    Green, J.2    Manegold, C.3
  • 18
    • 14544270307 scopus 로고    scopus 로고
    • First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study
    • Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178-84.
    • (2005) J Clin Oncol , vol.23 , pp. 1178-1184
    • Vogel, C.L.1    Wojtukiewicz, M.Z.2    Carroll, R.R.3
  • 19
    • 0036467835 scopus 로고    scopus 로고
    • Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer
    • Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727-31.
    • (2002) J Clin Oncol , vol.20 , pp. 727-731
    • Holmes, F.A.1    O'Shaughnessy, J.A.2    Vukelja, S.3
  • 20
    • 84891724520 scopus 로고    scopus 로고
    • Available at:, Accessed January 26, 2007
    • FDA approved label for Neulasta. Available at: http://www.fda.gov/Cder/ biologics/products/pegfamg013102.htm. Accessed January 26, 2007.
    • FDA approved label for Neulasta
  • 21
    • 85039213900 scopus 로고    scopus 로고
    • Available at:, Accessed March 16, 2007
    • FDA approval for Neupogen. Available at: http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm. Accessed March 16, 2007.
    • FDA approval for Neupogen
  • 22
    • 0027732691 scopus 로고
    • The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy
    • Glaspy J, Bleecker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993;29A(suppl 7): S23-S30.
    • (1993) Eur J Cancer , vol.29 A , Issue.SUPPL. 7
    • Glaspy, J.1    Bleecker, G.2    Crawford, J.3
  • 23
    • 33644833866 scopus 로고    scopus 로고
    • Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: Findings from a large population-based cohort
    • Du XL, Lairson DR, Begley CE, et al. Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort. J Clin Oncol. 2005;23:8620-28.
    • (2005) J Clin Oncol , vol.23 , pp. 8620-8628
    • XL, D.1    Lairson, D.R.2    Begley, C.E.3
  • 24
    • 0032703442 scopus 로고    scopus 로고
    • Use of hematopoietic colonystimulating factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology
    • Bennett CL, Weeks JA, Somerfield MR, et al. Use of hematopoietic colonystimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1999;17:3676-81.
    • (1999) J Clin Oncol , vol.17 , pp. 3676-3681
    • Bennett, C.L.1    Weeks, J.A.2    Somerfield, M.R.3
  • 25
    • 0142240826 scopus 로고    scopus 로고
    • Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy
    • Available at:, Accessed April 22
    • Scott SD, Chrischilles EA, Link BK, et al. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm. 2003;9(2)(suppl): 15-21. Available at: http://www.amcp.org/data/jmcp/index_suppv21.pdf. Accessed April 22, 2007.
    • (2007) J Manag Care Pharm. 2003 , vol.9 , Issue.2 SUPPL. , pp. 15-21
    • Scott, S.D.1    Chrischilles, E.A.2    Link, B.K.3
  • 26
    • 85039238890 scopus 로고    scopus 로고
    • Association of IV antibiotic use and hospitalization with filgrastim (F) and pegfilgrastim (PegF) utilization in a community oncology clinic sample. Poster
    • presented at: December 7-11, New Orleans, LA
    • Former B, Stolshek B, Mao Q, et al. Association of IV antibiotic use and hospitalization with filgrastim (F) and pegfilgrastim (PegF) utilization in a community oncology clinic sample. Poster presented at: 38th ASHP Midyear Clinical Meeting and Exhibition; December 7-11, 2003; New Orleans, LA.
    • (2003) 38th ASHP Midyear Clinical Meeting and Exhibition
    • Former, B.1    Stolshek, B.2    Mao, Q.3
  • 27
    • 0034003365 scopus 로고    scopus 로고
    • Growth factor usage patterns and outcomes in the community setting: Collection through a practice-based computerized clinical information system
    • Swanson G, Bergstrom K, Stump E, et al. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol. 2000;18:1764-70.
    • (2000) J Clin Oncol , vol.18 , pp. 1764-1770
    • Swanson, G.1    Bergstrom, K.2    Stump, E.3
  • 28
    • 0142157169 scopus 로고    scopus 로고
    • Evaluating medication effects outside of clinical trials: New-user designs
    • Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-20.
    • (2003) Am J Epidemiol , vol.158 , pp. 915-920
    • Ray, W.A.1
  • 29
    • 84992750713 scopus 로고    scopus 로고
    • Available at:, Accessed December 5, 2005
    • IMS Health Web site. Available at: http://www.imshealth.com/. Accessed December 5, 2005.
    • IMS Health Web site
  • 30
    • 0023092594 scopus 로고
    • A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
    • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
    • (1987) J Chronic Dis , vol.40 , pp. 373-383
    • Charlson, M.E.1    Pompei, P.2    Ales, K.L.3
  • 31
    • 85039225306 scopus 로고    scopus 로고
    • U.S. Dept. of Health and Human Services: Health Insurance Portability and Accountability Act (HIPAA). Available at: http://www.hhs.gov/ocr/ hipaa/. Accessed May 3, 2007.
    • U.S. Dept. of Health and Human Services: Health Insurance Portability and Accountability Act (HIPAA). Available at: http://www.hhs.gov/ocr/ hipaa/. Accessed May 3, 2007.
  • 33
    • 33745989223 scopus 로고    scopus 로고
    • Recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline; 2006 update
    • Smith TC, Khatcheressian J, Lyman G, et al. Recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline; 2006 update. J Clin Oncol. 2006;24:1-19,3187-3205.
    • (2006) J Clin Oncol , vol.24
    • Smith, T.C.1    Khatcheressian, J.2    Lyman, G.3
  • 34
    • 28244502087 scopus 로고    scopus 로고
    • Observational studies of drugs and mortality
    • Ray WA. Observational studies of drugs and mortality. N Engl J Med. 2005;353:2319-21.
    • (2005) N Engl J Med , vol.353 , pp. 2319-2321
    • Ray, W.A.1
  • 35
    • 0033847784 scopus 로고    scopus 로고
    • Marginal structural models and causal inference in epidemiology
    • Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-60.
    • (2000) Epidemiology , vol.11 , pp. 550-560
    • Robins, J.M.1    Hernan, M.A.2    Brumback, B.3
  • 36
    • 77649173768 scopus 로고
    • Longitudinal data analysis using generalized linear models
    • Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
    • (1986) Biometrika , vol.73 , pp. 13-22
    • Liang, K.1    Zeger, S.2
  • 37
    • 10344230139 scopus 로고    scopus 로고
    • Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study
    • Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004;22:4302-11.
    • (2004) J Clin Oncol , vol.22 , pp. 4302-4311
    • Lyman, G.H.1    Dale, D.C.2    Friedberg, J.3    Crawford, J.4    Fisher, R.I.5
  • 38
    • 1542753592 scopus 로고    scopus 로고
    • Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices
    • Lyman GH, Dale DC, Crawford J. Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524-31.
    • (2003) J Clin Oncol , vol.21 , pp. 4524-4531
    • Lyman, G.H.1    Dale, D.C.2    Crawford, J.3
  • 39
    • 33746904664 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network, Version 1.2007. Available at:, Accessed January 26
    • National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology Myeloid growth factors. Version 1.2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. Accessed January 26, 2007.
    • (2007) NCCN clinical practice guideline in oncology Myeloid growth factors
  • 40
    • 85039182821 scopus 로고    scopus 로고
    • Agency for Healthcare Research and Quality Outcomes of Pharmaceutical Therapy Program (OPT) update. AHRQ Publication No. 04-R205, Agency for Healthcare Research and Quality, Rockville, MD: Agency for Healthcare Research and Quality Available at: http://www.ahrq.gov/clinic/ pharmtherapy/optupdat.htm. Accessed June 2004.
    • Agency for Healthcare Research and Quality Outcomes of Pharmaceutical Therapy Program (OPT) update. AHRQ Publication No. 04-R205, Agency for Healthcare Research and Quality, Rockville, MD: Agency for Healthcare Research and Quality Available at: http://www.ahrq.gov/clinic/ pharmtherapy/optupdat.htm. Accessed June 2004.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.